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In summary, the two papers show that the low-affinity 
liver isoform of glucose transporter is found in cells that 
primarily export glucose, such as those cells involved 
with transepithelial glucose transport or gluconeo- 
genesis, whereas the high-affinity erythrocytelbrain 
transporter is found in cells that primarily take up 
glucose from plasma. Important and novel aspects of 
these studies include the demonstration of two types of 
transporters coexisting in the kidney, the type and 
density correlating with direction of transport (influx or 
efflux) and energy requirements, and the localization of 
a liver-type glucose carrier to  the basolateral membrane 
of differentiated small intestinal surface cells, con- 
firming their role in nutrient absorption. Unques- 
tionably, a new and useful research tool for studying 
transmembrane glucose transport has been added to the 
investigator’s armamentarium. 
JONATHAN D. KAUNITZ, M.D. 
Division of Gastroenterology 
Department of Medicine 
University of California at Los Angeles 
Los Angeles, California 
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TREATMENT OF HEPATOCELLULAR CARCINOMA 
Venook AP, Stagg RJ, Lewis BJ, Chase JL ,  Ring EJ, 
Maroney TP, Hohn DC. Chemoembolization for hepa- 
tocellular carcinoma. J Clin Oncol 1990;8:1108-1114. 
ABSTRACT 
Fifty-one patients with unresectable hepatocellular 
carcinoma were treated by embolization of the hepatic 
artery with Gelfoam powder, contrast material and 
three chemotherapeutic agents (doxorubicin, mito- 
mycin, cisplatin). Twelve patients (24%) had a partial 
response with a decrease in the tumor diameter by at 
least 50%, 13 patients (26%) had only minor responses, 
12 (24%) had stabilization of disease and the remainder 
had progressive disease. Tumor liquefaction was noted 
on computed tomographic scanning in 70% of patients, 
and 23 of 34 patients with elevations in serum alpha- 
fetoprotein values had a greater than 50% reduction 
following treatment. The median patient survival time 
from treatment was 207 days. Most patients experi- 
enced transient pain, fever, nausea and elevations in 
serum aminotransferase activities as a result of 
therapy. Ascites developed in 14 patients. There were 
two treatment-related deaths: one from tumor hemor- 
rhage and one from liver failure. Chemoembolization 
therefore appears to have significant activity in pa- 
tients with hepatocellular carcinoma and is relatively 
well tolerated. 
Franco D, Capussotti L, Smadja C, Bouzari H, Meakins 
J ,  Kemeny F, Grange D, et al. Resection of hepatocellular 
carcinoma: results in 72 European patients with cir- 
rhosis. Gastroenterology 1990;98:733-738. 
ABSTRACT 
This study reports the results of resection in 72 
cirrhotic patients with hepatocellular carcinoma from 
Europe. One and 3 year survival rates were 68% and 
51% respectively. Survival was significantly higher in 
Child’s class A than in class B or C patients. Patients 
with a thickly encapsulated tumor lived longer than 
those with an infiltrating tumor and also had a signif- 
icantly lower recurrence rate. There was no rela- 
tionship between the size of the tumor or the presence 
of symptoms and survival. These data suggest that good 
results can be achieved by resection of hepatocellular 
carcinoma in European cirrhotic patients. A thickly 
encapsulated tumor and good liver function are the 
main determinants of low cancer recurrence and high 
survival. 
COMMENTS 
HCC is one of the most common cancers worldwide, 
although it occurs relatively infrequently in the de- 
veloped Western world (1). Typically HCC is seen at an 
advanced stage with extensive intrahepatic disease and 
metastases to lung, bone, adrenal gland or regional 
lymph nodes. It is also usually associated with sig- 
nificant liver disease, particularly cirrhosis (2). Because 
of this late presentation and association with cirrhosis, 
HCC has a grave prognosis, with survival times being 
measured in weeks to months. No effective therapy has 
been available for advanced HCC, although surgical 
resection has been considered potentially curative if 
carried out at an early stage. Within the past few years, 
a significant shift in emphasis has occurred with the 
attempt to diagnose HCC at an early, asymptomatic 
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phase using various screening techniques in high-risk 
individuals. 
The two papers summarized above represent the two 
extremes of treatment for HCC. The first, by Venook and 
colleagues from San Francisco, describes the palliative 
use of chemoembolization for advanced, symptomatic 
HCC, whereas the second paper describes the results of 
resection for small, asymptomatic HCC in two European 
centers. Venook et al. described embolization of the 
hepatic artery feeding the tumor with a Gelfoam plug 
mixed with contrast material and three chemothera- 
peutic agents idoxorubicin, mitomycin and cisplatin) in 
51 patients with HCC. The authors emphasize that they 
injected enough Gelfoam into the artery to cause 
stagnation of flow but not total occlusion. Thus they 
were able to administer this therapy to each patient on 
several occasions. The best response noted was a greater 
than 50% decrease in diameter of the tumor. This 
occurred in 24% of patients. Tumor liquefaction was 
noted in 70% of cases, and serum a-fetoprotein (AFP) 
levels fell by half in 68% of patients in whom it was 
elevated. 
Unfortunately, chemoembolization was associated 
with significant complications, including two treatment- 
related deaths and severe morbidity in some cases, with 
fever, pain, nausea and vomiting and the development of 
liver failure. It is not clear, then, whether patients 
derived any real benefit from this therapy. The authors 
suggest that the mean survival time of patients in this 
study (7 mo) was prolonged beyond that of historical 
controls. Transcatheter arterial embolization (TAE) is 
an established mode of therapy for HCC in some cen- 
ters and appears to prolong survival marginally (3). 
The premise for using this treatment is that HCC 
derives all or most of its blood supply directly from the 
hepatic artery, whereas the remainder of the liver 
depends on the portal vein for most of its blood supply. 
However, the effect of TAE has not been subjected to 
controlled clinical trials. The intraarterial infusion of 
chemotherapeutic agents at the time of embolization 
may have theoretical benefits, but most of the effect 
may be caused by occlusion of the blood supply of the 
tumor (4). 
Most reports of resection of small HCCs from cirrhotic 
livers have come from Japan, Taiwan and China, where 
this tumor occurs frequently (5). The report by Franco 
and colleagues describes their experience with 72 pa- 
tients at  two hospitals, one in northern Italy and the 
other in France. In most cases, the tumor was detected 
at  routine screening by ultrasound examination or 
serum AFP measurement in asymptomatic patients. 
The authors found that patients with Child class A 
cirrhosis had a significantly better prognosis after 
surgery and that the tumor was less likely to recur if it 
was of the slowly expanding type with a thick capsule. 
Deaths after the operation occurred in 7% of the 
patients, mostly caused by bleeding esophageal varices. 
The patients had other complications after the operation 
related to their cirrhosis. including ascitic fluid leaking 
of liver failure (8%). On follow-up after surgery, HCC 
recurred in 16 patients (22%). 
Although both reports are positive in tone, they serve 
to emphasize the dismal outlook for patients with HCC. 
Although long-term survival is possible after surgical 
resection, it remains to be proven whether the use of 
screening programs to detect HCC at an early stage 
actually improves the prognosis of this condition or 
whether their reported success is caused by lead-time 
bias. Thus small HCCs may represent a very early stage 
of disease that might take as long as several years before 
clinical symptoms appear. The apparent prolongation of 
survival may simply represent this same interval that 
the tumor would have taken naturally before clinical 
appearance. 
Liver transplantation has also been considered to be a 
curative modality of therapy in some patients with HCC 
that is found incidentally at the time of surgery (6). 
Other investigators have chosen to use other means of 
local destruction of small tumors in cirrhotic livers, such 
as local injection of alcohol (7). This appears to be able 
to  destroy viable tumors less than 3 cm in diameter and 
is associated with minimal morbidity and mortality. 
Traditional systemic or regional chemotherapy has 
not proven effective in HCC. Response rates of 8% to 
42% have been reported (8, 9). These rates are not 
dissimilar from those found by Venook in the study 
described above. Order et al. have described some 
complete responses to targeted radiation therapy with 
radiolabeled antiferritin (8, 9). Responses to this 
treatment appeared to be better in patients who did not 
have elevated serum AFP values. However, preliminary 
results of a controlled trial have not confirmed the 
efficacy of this imaginative approach (10). Further study 
of chemoembolization is warranted, perhaps in patients 
with less advanced disease who have the potential for 
better responses. Other means of targeting chemo- 
therapy to the liver or to the tumor directly should be 
explored. Lipiodol is an oil-based contrast agent that 
appears to be taken up and trapped specifically in HCC 
tissue. This phenomenon has proved to be useful for 
radiological imaging of HCC. However, Lipiodol appears 
to have some direct antitumor effect when injected into 
the hepatic artery and has also been mixed with 
chemotherapeutic agents with some promising results 
(10). Lipiodol has also been used to target radioiodine to  
HCC (Dusheiko GM, Personal communication). 
Many of the therapeutic approaches described above 
appear to be of marginal benefit and therefore need to be 
studied in controlled trials. This has rarely been done in 
the Far East, where many patients are available for such 
studies. In the United States and Europe, controlled 
trials of larger numbers of patients will almost certainly 
require the cooperation of many medical centers. For 
such multicenter controlled trials to be contemplated, 
however, investigators need to have a format for 
planning and executing such trials. At a recent con- 
ference on HCC held at the National Institutes of Health 
in Bethesda, Maryland, investigators began discussing 
such cooperative efforts. Many felt that much of the through the abdominal wall (19%)>nd the developmeni 
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HCC terminology needs to be standardized first. For 
example, what is an “incidental HCC”? Is this the same 
as a “small” HCC or an “asymptomatic HCC”? What 
tumor diameter should be used to define small HCC? 
Both 3 cm and 5 cm have been proposed. It was 
emphasized that not all HCCs are the same in biological 
behavior. They may vary depending on histological type 
(the fibrolamellar type is slower growing with a better 
prognosis), on cause (hepatitis B reactivation may occur 
in association with chemotherapy), on whether cirrhosis 
is present and perhaps on whether serum AFP values 
are elevated. In any trial these factors should be 
assessed, and perhaps patients enter into studies strat- 
ified according to some of these variables. Better means 
of assessing the response to therapy need to be used. One 
very promising approach is the use of a computer 
program, developed at Johns Hopkins Hospital, to 
measure tumor volume (10). 
In summary, therapies that may significantly benefit 
patients with HCC are being developed. Their worth will 
eventually need to be tested in controlled clinical trials 
requiring large numbers of patients. In the developed 
Western world, where HCC is relatively uncommon, 
such trials may need to be conducted in multiple centers 
using standardized terminology and methodology. 
ADRIAN M. DI BISCEGLIE, M.D. 
Liver Diseases Section 
National Institute of Diabetes and Digestive 
and Kidney Diseases 
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MORE ON GLUCOSE TRANSPORTERS: 
THE ACINAR ORGANIZATION FOR HEPATIC 
GLUCOSE TRANSPORT 
Tal M,  Schneider DL, Thorens B, Lodish HF. Restricted 
expression of the erythroidbrain glucose transporter 
isoform to perivenous hepatocytes in rats: modulation 
by glucose. J Clin Invest 1990;86:986-992. 
ABSTRACT 
The “erythroidhrain” glucose transporter (GT) 
isoform is expressed only in a subset of hepatocytes, 
those forming the first row around the terminal he- 
patic venules, while the “liver” GT is expressed in all 
hepatocytes. After 3 d of starvation, a three- to fourfold 
elevation of expression of the erythroidbrain GT 
mRNA and protein is detected in the liver as a whole; 
this correlates with the expression of this GT in more 
hepatocytes, those forming the first three to four rows 
around the hepatic venules. Starvation-dependent ex- 
pression of the erythroidfbrain GT on the plasma 
membrane of these additional hepatocytes is lost 
within 3 h of glucose refeeding; however, by immuno- 
blotting we show that the protein is still present. Its 
loss from the surface is possibly explained by internal- 
ization. 
COMMENTS 
Transport of glucose across the plasma membrane of 
mammalian cells can occur by a secondary active 
transport process such as in the small intestine or by 
facilitated diffusion. Facilitated diffusion of glucose is 
mediated by a family of related transport proteins 
having different tissue distribution and diverse regu- 
lation. To date, five functional facilitated diffusion 
transport systems and a pseudogene have been iden- 
tified (Table 1). These proteins vary in size from 492 
amino acids to 524 amino acids (1). Among the five 
functional forms a 39% to 65% identity and a 50% to 76% 
similarity exists. Twenty-six percent of the residues are 
identical in all five forms, whereas 13% are conservative 
substitutions (1). Two species of facilitated diffusion 
glucose transporters have been found in the liver, a less 
abundant erythroidbrain form or glut-1 and the main 
liver form or glut-2. These forms differ considerably in 
the Michaelis constant (K,) for glucose. Glut-1 has a K, 
of 1 to 2 mmol/L and thus is saturated at physiological 
concentrations of serum glucose (about 5 mmol/L). In 
contrast, glut-2 has a K, of 15 to 20 mmol/L. Therefore 
hepatic glucose homeostasis is subserved by the low- 
affinity liver isotype or glut-2. 
The two rat liver isoforms respond differently to 
conditions of fasting and refeeding and to experimental 
diabetes and insulin replacement. These different pat- 
terns of response led investigators to propose that these 
transporters are regulated by different mechanisms (2). 
In this paper, the authors, using polyclonal antibodies 
that specifically recognize either glut-1 or glut-2, immu- 
nolocalized the hepatocytes expressing these trans- 
porters. They observed that under control conditions, 
glut-2 was expressed in all hepatocytes. In contrast, 
